| 证券代码 | ZGNX.O |
| 证券名称 | Zogenix Inc |
| 证券类型 | 美股 |
| 上市场所 | 纳斯达克交易所 |
| 上市板块 | 主板 |
| 发行方式 | 公开发售 |
| 首发上市日 | 2010-11-23 |
| 首发价格(元) | 4 USD |
| 首发数量(股) | 14000000 |
| 首发募资额(元) | 56,000,000.00 USD |
| 首发主承销商 | Leerink Swann LLC,Wells Fargo Securities, LLC |
| 货币单位 | USD |
| 公司名称 | Zogenix, Inc. |
| 注册地址 | 美国特拉华州 |
| 办公地址 | 5858 Horton Street, Suite 455, Emeryville, California, USA |
| 成立日期 | 2006-05-11 |
| 董事会主席 | Cam L. Garner |
| 公司属地 | United States 美国 |
| 公司网址 | www.zogenix.com |
| 电话 | +1 (510) 550-8300 |
| 传真 | - |
| 公司简介 | Zogenix, Inc. (Nasdaq: ZGNX) is a pharmaceutical company dedicated to developing therapies for people living with severe central nervous system (CNS) disorders who have limited or no treatment options. Led by a team of experts in rare disease development and CNS conditions, Zogenix is rapidly advancing the clinical investigation and development of ZX008 (fenfluramine hydrochloride) for patients with severe, rare epilepsies, including Dravet and Lennox-Gastaut syndromes. |